Drug Trial Radar · NCT06845241
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Feb 2025
Primary completion
Jul 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.
Conditions
- Relapsed or Refractory Non-Hodgkin Lymphoma
Interventions
ICP-490Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0Time frame: Through study completion,an average of 3 years
- Incidence, type, and severity of dose-limiting toxicities (DLTs);Time frame: Through study completion,an average of 3 years
- Recommended Phase 2 Doses(RP2Ds) and/or maximum tolerated doses(MTDs).Time frame: Through study completion,an average of 3 years
- ORR assessed according to the Lugano criteria (Cheson 2014).Time frame: Through study completion,an average of 3 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Henan Cancer Hosptital
Zhengzhou, Henan, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.